PLK1 and acute lymphoblastic leukemia: In ALL, various targets have been successfully silenced by RNAi, such as Polo-like kinase 1 (Plk1), CD22ΔE12, CSF1R, JAK1 and FLT3 [34–36], all of which highlights the versatility of using RNAi for ALL therapy.